Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 27;21(1):489.
doi: 10.1186/s12879-021-06164-x.

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Toshie Manabe  1   2 , Dan Kambayashi  3   4 , Hiroyasu Akatsu  3 , Koichiro Kudo  5   6
Affiliations
Meta-Analysis

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Toshie Manabe et al. BMC Infect Dis. .

Abstract

Background: Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited.

Methods: We conducted a systematic review of published studies reporting the efficacy of favipiravir against COVID-19. Two investigators independently searched PubMed, the Cochrane Database of Systematic Reviews, MedRxiv, and ClinicalTrials.gov (inception to September 2020) to identify eligible studies. A meta-analysis was performed to measure viral clearance and clinical improvement as the primary outcomes.

Results: Among 11 eligible studies, 5 included a comparator group. Comparing to the comparator group, the favipiravir group exhibited significantly better viral clearance on day 7 after the initiation of treatment (odds ratio [OR] = 2.49, 95% confidence interval [CI] = 1.19-5.22), whereas no difference was noted on day 14 (OR = 2.19, 95% CI = 0.69-6.95). Although clinical improvement was significantly better in the favipiravir group on both days 7 and 14, the improvement was better on day 14 (OR = 3.03, 95% CI = 1.17-7.80) than on day 7 (OR = 1.60, 95% CI = 1.03-2.49). The estimated proportions of patients with viral clearance in the favipiravir arm on days 7 and 14 were 65.42 and 88.9%, respectively, versus 43.42 and 78.79%, respectively, in the comparator group. The estimated proportions of patients with clinical improvement on days 7 and 14 in the favipiravir group were 54.33 and 84.63%, respectively, compared with 34.40 and 65.77%, respectively, in the comparator group.

Conclusions: Favipiravir induces viral clearance by 7 days and contributes to clinical improvement within 14 days. The results indicated that favipiravir has strong possibility for treating COVID-19, especially in patients with mild-to-moderate illness. Additional well-designed studies, including examinations of the dose and duration of treatment, are crucial for reaching definitive conclusions.

Keywords: COVID-19; Clinical improvement; Favipiravir; SARS-CoV-2; Viral clearance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram. N is the number of articles
Fig. 2
Fig. 2
Forrest plots for viral clearance for patients with COVID-19 who were treated with favipiravir or a comparator for (a) 7 or (b) 14 days
Fig. 3
Fig. 3
Proportions of patients with COVID-19 who achieved viral clearance on (a) 7 and (b) 14 days from the initiation of treatment
Fig. 4
Fig. 4
Forrest plots of clinical improvement for patients with COVID-19 treated with favipiravir for (a) 7 and (b) 14 days
Fig. 5
Fig. 5
Proportions of patients with COVID-19 who had clinical improvement until (a) 7 and (b) 14 days from the initiation of treatment
Fig. 6
Fig. 6
Forrest plots of the number of adverse events for patients with COVID-19 who were treated with favipiravir
See this image and copyright information in PMC

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re... (Accessed April 5, 2020).
    1. World Health Organization. Weekly epidemiological update-1 December 2020. Available at https://www.who.int/publications/m/item/weekly-epidemiological-update%2D... (Accessed December 5, 2020).
    1. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463. doi: 10.2183/pjab.93.027. - DOI - PMC - PubMed
    1. FUJIFILM Toyama Chemical Co., Ltd. Drug Interview form. Avigan® http://fftc.fujifilm.co.jp/med/abigan/pack/pdf/abigan_if_01.pdf. Accessed 5 Apr 2020.